Hydroxyurea does not enhance the anti-HIV activity of low-dose tenofovir disoproxil fumarate

Steven G. Deeks, Patricia Barditch-Crovo, Ann Collier, Anna Smith, Michael Miller, Ian McGowan, Dion F. Coakley

Research output: Contribution to journalArticlepeer-review


Tenofovir disoproxil fumarate (DF) is an adenosine analogue with significant activity against HIV-1. Hydroxyurea decreases the intracellular concentrations of deoxyadenosine triphosphate, the active metabolite of adenosine. We therefore tested the hypothesis that hydroxyurea could enhance the anti-HIV activity of low-dose tenofovir in vivo. Eight patients received tenofovir DF, 75 mg, plus hydroxyurea, 500 mg bid, for 28 days. Changes in plasma HIV RNA levels were compared with a previously studied cohort of patients treated with tenofovir DF, 75 mg once daily (n = 8), or tenofovir placebo (n = 12). The median change in HIV RNA levels after 28 days of continuous treatment was -0.01 log10 copies/ml for tenofovir placebo, -0.33 log10 copies/ml for tenofovir 75 mg once daily, and -0.22 log10 copies RNA/ml for tenofovir plus hydroxyurea. The difference between placebo and tenofovir-treated groups was significant (p < .05); however, the difference between the tenofovir and tenofovir plus hydroxyurea groups was not significant (p = .90). We conclude that hydroxyurea does not significantly enhance the antiviral activity of low-dose tenofovir.

Original languageEnglish (US)
Pages (from-to)336-339
Number of pages4
JournalJournal of Acquired Immune Deficiency Syndromes
Issue number4
StatePublished - Dec 1 2001


  • Antiretroviral therapy
  • HIV-1
  • Hydroxyurea
  • Tenofovir

ASJC Scopus subject areas

  • Infectious Diseases
  • Pharmacology (medical)


Dive into the research topics of 'Hydroxyurea does not enhance the anti-HIV activity of low-dose tenofovir disoproxil fumarate'. Together they form a unique fingerprint.

Cite this